Effect of <i>Lactobacillus casei</i> strain Shirota-fermented milk on metabolic abnormalities in obese prediabetic Japanese men: a randomised, double-blind, placebo-controlled trial

• NAITO Eiichiro

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• YOSHIDA Yasuto

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• KUNIHIRO Satoru

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• MAKINO Kumiko

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• KASAHARA Kohei

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• KOUNOSHI Yuu

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• AIDA Masanori

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• HOSHI Ryotaro

  Faculty of Research and Development, Yakult Honsha Co., Ltd., 1-1-19 Higashishinbashi, Minato-ku, Tokyo 105-8660, Japan

• WATANABE Osamu

  Faculty of Research and Development, Yakult Honsha Co., Ltd., 1-1-19 Higashishinbashi, Minato-ku, Tokyo 105-8660, Japan

• IGARASHI Tomoki

  Faculty of Research and Development, Yakult Honsha Co., Ltd., 1-1-19 Higashishinbashi, Minato-ku, Tokyo 105-8660, Japan

• MIYAZAKI Kouji

  Yakult Central Institute, 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan

• ITO Hideki

  Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan

抄録

An obesity-related prediabetic state is characterised by metabolic abnormalities such as post-glucose load hyperglycaemia and dyslipidaemia and consequently increases the risk for type 2 diabetes and cardiovascular disease. This study aimed to investigate the effects of Lactobacillus casei strain Shirota (LcS) on metabolic abnormalities in obese prediabetic subjects in a randomised, double-blind, placebo-controlled trial. Herein, 100 obese subjects (body mass index ≥25), who had moderate post-load hyperglycaemia (1-hr post-load plasma glucose (PG) levels ≥180 mg/dl during the oral glucose tolerance test), consumed LcS-fermented milk or placebo milk daily for 8 weeks. The post-load PG and fasting blood markers were evaluated. Although post-load PG levels were not significantly different between the groups, 1-hr post-load PG, glycoalbumin, and HbA1c levels decreased at 8 weeks compared with the baseline levels only in the LcS group (p=0.036, p=0.002, and p=0.006, respectively). The reduction in glycoalbumin levels was statistically significantly greater in the LcS group than in the placebo group (p=0.030). Stratified analyses revealed significantly improved 1-hr post-load PG and glycoalbumin levels in the LcS group compared with the placebo group among subjects with severe glucose intolerance (2-hr post-load PG levels higher than the median at baseline; p=0.036 and p=0.034, respectively). In terms of lipidic outcomes, total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels were significantly lower in the LcS group than in the placebo group (p=0.023, p=0.022, and p=0.008, respectively). These findings suggest that LcS may favourably affect metabolic abnormalities in obese prediabetic subjects, though the effects on glycaemic control may be limited.

収録刊行物

• Bioscience of Microbiota, Food and Health

  Bioscience of Microbiota, Food and Health 37 (1), 9-18, 2018

  BMFH出版会

キーワード

• probiotics
• oral glucose tolerance test
• glycaemic control
• glycoalbumin
• dyslipidaemia

詳細情報

• CRID: 1390282680388704000
• NII論文ID: 130006321447
• DOI: 10.12938/bmfh.17-012
• ISSN: 21863342
• Web Site: https://www.jstage.jst.go.jp/article/bmfh/37/1/37_17-012/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2018245773
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可